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ABSTRACT
Background: Isocyanates have become one of the most important causes of occupational asthma in industri-
alized countries. Increased exhaled nitric oxide (eNO) levels have been shown to be associated with allergic
airway inflammation. The objective of this study was to investigate the influence of isocyanate on eNO levels
and to elucidate whether the latter are associated with specific sensitization andor unspecific bronchial hyper-
responsiveness (BHR). Additionally, we wanted to compare eNO changes of smokers and non-smokers．
Methods: We determined eNO during diagnostic isocyanate challenges in workers with suspected isocyanate
asthma．
Results: Fourteen of 22 symptomatic isocyanate workers showed BHR and five of these 14 developed an
asthmatic response upon challenge with methylene diphenyl diisocyanate (MDI). In comparison with the group
without BHR, subjects with BHR had higher basal eNO and a significant increase in eNO 22 hrs after MDI chal-
lenge. Four of the asthmatic responders and six of the nine MDI non-responders with BHR revealed an eNO in-
crease of > 30%. There was also a positive association between the eNO change and the increase in airway
resistance in isocyanate workers with BHR. The highest eNO change was found in subjects with IgE-mediated
sensitization to MDI and low MDI thresholds. Only one of the eight MDI non-responders without BHR exhibited
an eNO increase of > 30%.
Conclusions: Isocyanate workers with BHR show increased MDI responses both of airway resistance and of
the inflammatory marker eNO. eNO measurement is obviously a new suitable tool for monitoring isocyanate
workers under respiratory risk．
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INTRODUCTION
Exhaled nitric oxide (eNO) has been identified as a
new marker of allergic airway imflammation.1-4 Sub-
jects suffering from asthmatic andor rhinitic symp-
toms show increased eNO levels 5,6 and eNO in-
creases were described to precede sputum eosino-
philia and lung function deterioration in asthmatics.7,8
Since cigarette smoke has a high NO concentration,
smokers have decreased eNO values, probably due
to the suppression of endogenous NO production.9
Several studies demonstrate that inhalative allergen
exposure of sensitised subjects results in inflamma-
tory reactions of the airways which are associated
with elevated eNO levels . 1,3,5,9 So far , eNO has
scarcely been analysed in workers exposed to isocy-
anates, worldwide one of the most frequent causes of
occupational asthma.10 Isocyanates are not classic al-
lergens since approximately 80% of affected workers
do not show evidence of IgE-mediated sensitiza-
tion.11-15 To the best of our knowledge, this is the
first study dealing with eNO in isocyanate workers
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(with the exception of a preliminary investigation of
our group).6 In our initial study of 9 subjects,6 eNO
increased in some subjects 22 hrs after inhalation
challenge with methylene diphenyl diisocyanate
(MDI). However, statistical analysis and standardiza-
tion (particularly with regard to the exhalation rate)
according to ERS and ATS recommendations pub-
lished later were not possible in this initial investiga-
tion. These deficiencies were overcome in the pre-
sent study which was designed to evaluate the rela-
tionship between isocyanate-induced eNO changes
(∆eNO) and the outcome of the specific challenge
test as well as of methacholine challenge testing .
Only patients subjected to MDI as well as meth-
acholine challenge tests were included in the present
paper．
METHODS
22 subjects consecutively undergoing medical exami-
nation for suspected isocyanate asthma in our insti-
tute took part in this study. The subjects had worked
in chemical plants (n = 7), foam production (n = 3),
coating (n = 4), casting (n = 2) or in rock consolida-
tion of hard coal mines (n = 6) where MDI was used.
In all subjects symptoms of cough, wheezing andor
chest tightness had developed after working for at
least one year with MDI.
Four patients were current cigarette smokers (2 to
12 packyears ; 4 to 25 cigarettes per day), ten were
ex-smokers who had smoked for more than two years
and eight had never smoked. Smokers were asked to
refrain from smoking 1 hr before testing. Five sub-
jects were treated with inhalative corticosteroids at
the time of the study．
The subjects were asked not to take any drug 12
hrs before the investigation.
Specific IgE antibodies to the conjugate MDI-HSA
were determined by the CAP system (Pharmacia
Uppsala, Sweden ; 16) ; values above 0.35 kUL were
considered positive．
Lung function measurement , methacholine chal-
lenge testing and occupational-type MDI challenge
were performed using a bodyplethysmograph as pre-
viously described.17 Patients were categorized as hav-
ing bronchial hyperresponsiveness ( BHR ) if
PD40 ; 0.5(kPa x s) sGaw was < 0.3 mg methacholine.
In the MDI challenge performed in a chamber, an
sRaw increase of at least 100% from basal values reach-
ing2 kPa*s was considered a positive result. Imme-
diate reactions occurred up to 1 hr, late reactions 2 to
22 hrs post challenge. We started the occupational-
type MDI challenge with 3 ppb for 30 min followed by
5 ppb for 90 min if no asthmatic reaction occurred.13
Because of ethical reasons, the German occupational
exposure limit (OEL) of 5 ppb was not exceeded. In
two subjects, MDI challenge was stopped at 3 ppb
due to strong immediate asthmatic reactions, but all
others underwent the complete challenge test proto-
col.
sRaw as well as eNO were determined before, 1, 2,
4, 6 and 22 hrs post MDI challenge.
eNO measurements were performed according to
ATS recommendations18 with the exception of an ex-
piratory flow of 100 mLs with a chemiluminescense
analyser (CLD-88 ; ECO-Physics, Durnten, Switzer-
land) modified for on-line recording of eNO concen-
trations . The analyser has a sensitivity to NO be-
tween 0.1 ppb and 500 ppb, a resolution of 0.1 ppb,
and a response time of 0.5 s. The normal range of
eNO was determined in 25 healthy subjects with
regular lung function parameters (FVC, FEV1, sRaw) ;
their mean value at an expiratory flow of 100 mLs
was 7.7 ppb ; the 95% CI was 6.4―9.4 ppb. Regarding
this range, we consider basal eNO concentrations
9.5 ppb elevated values．
At the individual level, an eNO increase of > 30%
from basal values was interpreted as a preliminary
cut-off level of eNO changes after MDI challenge in
order to categorically differentiate between a remark-
able eNO increase and no substantial changes．
STATISTICAL METHODS
We used the Wilcoxon-signed rank test to determine
the significance of eNO changes after MDI chal-
lenges. The unpaired t-test or Kruskal-Wallis-test was
used to compare eNO values and lung function data
between groups．
Categorical variables were compared with chi-
square tests. Regression analysis was performed by
Spearman’s rank correlation coefficients to determine
the relationship between changes in sRaw and
changes in eNO duringafter MDI challenge. All re-
sults were expressed as means ± SEM. A value of p <
0.05 was considered significant.
RESULTS
Table 1 summarizes subjects’ characteristics and re-
sults of methacholine as well as of MDI challenge
tests.
14 of the 22 investigated MDI workers showed
BHR as evaluated by methacholine challenge testing.
Five of these 14 demonstrated an asthmatic response
during or post MDI challenge (MDI responders) ;
three had a dual response, two a late one. MDI con-
centrations eliciting these reactions were 3 ppb in two
subjects (both IgE-positive) and 5 ppb in three sub-
jects ( Fig. 1). In nine subjects with BHR , sRaw
changes did not fulfill the defined positive criteria
(Fig. 2). None of the eight subjects without BHR re-
vealed a remarkable change in sRaw after MDI chal-
lenge (Fig. 3).
According to the outcome of methacholine provo-
cation testing and MDI challenge, we could analyse
the time course of eNO in the following groups :
I. with BHR (n = 14)
-MDI responders (n = 5)；
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Table 1　Smoking habit and results of methacholine as wel as MDI chalenge tests
Changes 
eNO (% of 
basal value)
eNO 22 h 
post MDI 
chalenge 
(ppb)
eNO basal 
value (ppb)
Inhalative 
cortico-
steroid 
therapy
MDI-HSA-
specific IgE
Specifc 
chalenge 
test with 
MDI
Bronchial 
hyperes-
ponsivene-
ss
Smoking 
habit
Isocyanate 
worker no.
Workers with asthmatic response to MDI
－1923.529.1yesnegposyesex-smoker 1 (◆)
3114.010.7nonegposyessmoker 2 (◆)
8832.217.2noposposyesex-smoker 3 (△)
41510.32.0noposposyessmoker 4 (■)
50271.411.9noposposyesex-smoker 5 (＊)
Workers non-responding to MDI with BHR
－3411.817.8nonegnegyesex-smoker 6 
－104.55.0nonegnegyesex-smoker 7 
30014.03.5yesnegnegyesex-smoker 8 (◆)
46111.976.7nonegnegyesnon-smoker 9 
11964.429.4nonegnegyesnon-smoker10 
8930.115.9yesnegnegyesnon-smoker11 (●)
318.96.8yesnegnegyesex-smoker12 (○)
834.62.5nonegnegyessmoker13 (◆)
H28.48.2nonegnegyesex-smoker 14
Workers non-responding to MDI without BHR
－149.511.0nonegnegnonon-smoker15
06.36.3nonegnegnonon-smoker16
8510.05.4nonegnegnonon-smoker17
－98.79.6nonegnegnonon-smoker18
－154.45.2yesnegnegnonon-smoker19 (＊)
－193.84.7nonegnegnosmoker20 (◆)
19.08.9nonegnegnoex-smoker21
－2032.841 nonegnegnoex-smoker22
pos = positive result; neg = negative result.
-MDI non-responders with BHR (n = 9)；
II. without BHR (n = 8)
-MDI non-responders (n = 8)．
With regard to baseline eNO, there was no signifi-
cant tendency towards higher values in the two
groups with BHR compared with the group without
BHR (16.9 ± 5.7 ppb vs. 11.5 ± 4.3 ppb). Baseline eNO
was elevated in all but one of the MDI responders
(the exceptional case was a smoker), in four of the
nine MDI non-responders with BHR and in three of
the eight workers without BHR (Fig. 4). Of the four
smokers, three had normal baseline eNO values (the
exceptional case with a borderline eNO belonged to
the asthmatic group).
No significant changes in eNO occurred in the
three groups during the first four hrs post MDI chal-
lenge. 22 hrs post MDI challenge, there was a signifi-
cant increase in eNO only in subjects with BHR when
compared with their baseline eNO. Furthermore, the
eNO change was significantly higher in the BHR
group than in subjects without BHR (12.4 ± 5 ppb vs.
− 1 + 1.2 ppb ; P = 0.02) (Fig. 5).
Although there was no significant ∆eNO difference
between the two groups with BHR (MDI responders
vs . MDI non-responders with BHR) , the five asth-
matic responders showed on average a higher eNO
increase 22 hrs post MDI challenge than MDI non-
responders with BHR (16.2 ± 5 ppb vs. 10.3 ± 5 ppb ;
n.s.). The highest ∆eNO was seen in the three MDI
responders with MDI-HSA-specific IgE antibodies
(27.7 ± 13.7 ppb ; range 8 ― 60)(Fig. 6). The differ-
ences between the three groups were significant with
borderline P-values (p = 0.05), indicating a tendency
of increasing eNO changes post MDI challenge from
subjects without BHR to MDI non-responders with
BHR and so forth up to MDI responders. The differ-
ences were even more pronounced if eNO changes
were expressed in % from baseline (Fig. 7).
According to the preliminary cut-off of 30% of eNO
increase, 45 MDI responders , 69 of those with
BHR without MDI response, but only 18 of those
without BHR showed such an increase in eNO 22 hrs
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Fig. 1　Individual course of sRt post MDI chalenge test in isocyanate workers with asthmatic reactions (n = 5)
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Fig. 2　Individual course of sRt post MDI chalenge test in MDI non-responders with BHR (n = 9)
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post MDI challenge．
Smoking did not seem to influence eNO changes
22 hrs post MDI challenge (Fig. 7) as opposed to its
well documented effect on baseline eNO values.19,20
In subjects with BHR, a significant positive correla-
tion was found between eNO changes (% from base-
line) 22 hrs post challenge and the maximal changes
in sRaw (% from baseline) during the period 0―22 hrs
post MDI challenge (rs = 0.54, p = 0.04). Such an as-
sociation was not seen in workers without BHR．
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Fig. 3　Individual course of sRt post MDI chalenge test in MDI non-responders without BHR (n = 8)
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Fig. 4　Comparison of basal eNO values in the three groups of isocyanate workers
90
80
70
60
50
40
30
20
10
0
MDI non-responders
with BHR (n = 9)
MDI non-responders
without BHR (n = 8)
smoker
lgE-posltive
lgE-positive smoker
on corticosteroid therapy
upper limit
of normal
mean values
MDI responders
(n = 5)
eN
O
 (
pp
d)
DISCUSSION
The significant eNO increase after occupational-type
challenge test with MDI in most symptomatic work-
ers with BHR, which rarely occurs in the absence of
BHR, is remarkable, since isocyanates are thought to
have mainly irritative effects on the airways. The eNO
increase is more pronounced when MDI concentra-
tions below OEL elicit an asthmatic response and
when IgE-mediated sensitization to isocyanate is pre-
sent．
The strong eNO increases in IgE-sensitized MDI
workers are in accordance with findings in subjects
sensitized to environmental or occupational aller-
gens3,21-23 indicating allergic inflammation.
Interestingly, smoking isocyanate workers mostly
revealed normal baseline eNO values and always
demonstrated an eNO increase upon MDI challenge
in the presence of BHR ; i.e., they did not give evi-
dence for an impaired eNO response to MDI expo-
sure.
An eNO increase after exposure to occupational
substances is a more relevant parameter in occupa-
tional settings than an elevated baseline eNO value.
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Fig. 5　Changes in eNO post MDI chalenge test in subjects with BHR (MDI responders and MDI non-responders with 
BHR) and in the group without BHR (means ± SEM)
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Fig. 6　Individual eNO course post MDI chalenge test in isocyanate workers with asthmatic reactions (n = 5)
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In our study, ten of the 14 subjects with BHR were on
the basis of the preliminary cut-off of 30% correctly
classified and only one of the nine workers without
BHR was misclassified. Respective data of elevated
baseline eNO were 814 and 39. Thus, in addition to
the gold standard, the specific challenge test accom-
plished by lung function measurement, measurement
of eNO after defined inhalative exposures may be a
valuable tool to identify and monitor isocyanate work-
ers under respiratory risk , i . e. with occupational
asthma andor BHR. However, further studies with a
larger number of subjects are necessary to clarify the
prognostic value of eNO in such populations．
The results of our study are partly in accordance
with the report by Obata et al.24 who found an eNO
increase during late asthmatic reactions after plicatic
acid challenge in symptomatic responders as well as
in symptomatic non-responders. Surprisingly, in their
study a significant increase occurred in symptomatic
non-responders only . These authors also demon-
strated a significant correlation between the degree
of sputum eosinophilia and eNO levels after plicatic
acid challenges in subjects with suspected red cedar
asthma. They did not find a correlation between BHR
and eNO increase after challenge, however. In our
study, an association between BHR and a ∆eNO of >
30% was observed in 1014 subjects and an associa-
tion between corresponding negative findings in 78
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Fig. 7　Comparison of eNO changes 22 hrs post MDI chalenge in the three groups of isocyanate workers. There is a sig-
nificant trend of eNO changes among the three groups (p < 0.05; Kruskal-Walis test)
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subjects without BHR. Dupont et al.25 and Henriksen
et al.26 reported a significant positive association be-
tween BHR and elevated baseline eNO. Interestingly
and even more importantly , the latter authors ob-
served that a combination of these two tools is a very
specific finding in atopic asthma. Our study shows
that this also applies to proven isocyanate asthma and
to nearly half of the symptomatic isocyanate workers
with BHR without asthmatic response in the applied
challenge test . The latter group may include true
cases of isocyanate asthma showing “false negative”
MDI challenge test results due to cumulative effects
or much higher isocyanate concentrations in the
workplace than used in our challenge tests. It may
also include pre-stages of isocyanate asthma．
The findings of elevated baseline eNO and ∆eNO
22 hrs post MDI challenge as well as the positive as-
sociation between ∆eNO 22 hrs and sRaw increases
both in MDI responders and in MDI non-responders
with BHR suggest that there is no clear borderline
between these two groups．
We hypothesize that in susceptible individuals iso-
cyanate recruitment of inflammatory cells27 is associ-
ated with cellular activation in the airways resulting in
increased local NO production as well as BHR and is
followed by the development of MDI asthma. How-
ever, this hypothesis needs follow-up studies as well
as experimental investigations such as measurements
of bronchial NO production and diffusion, immuno-
cytochemicalhistochemical analyses of BAL compo-
nents as well as of biopsy specimens．
REFERENCES
1. Lopuhaa¨ CE, Koopmans JG, Jansen HM, van der Zee JS.
Similar levels of nitric oxide in exhaled air in non-
asthmatic rhinitis and asthma after bronchial allergen
challenge. Allergy 2003;58:300-305.
2. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M,
Bush A. Relationship between exhaled nitric oxide and
mucosal eosinophilic inflammation in children with diffi-
cult asthma, after treatment with oral prednisolone. Am. J.
Respir. Crit. Care Med. 2001;164:1376-1381.
3. Kharitonov SA, O’Connor BJ, Evans DJ, Barnes PJ.
Allergen-induced late asthmatic reactions are associated
with elevation of exhaled nitric oxide. Am.J. Respir. Crit.
Care Med. 1995;153:454-457.
4. Gratziou C, Lignos M, Dassiou M, Roussos C. Influence
of atopy on exhaled nitric oxide in patients with stable
asthma and rhinitis. Eur. Respir. J. 1999;14:897-901.
5. Thomassen MJ, Raychaudhuri B, Dweik RA et al. Nitric
oxide regulation of asthmatic airway inflammation with
segmental allergen challenge. J. Allergy Clin. Immunol.
1999;104:1174-1182.
6. Allmers H, Chen Z, Barbinova L, Marczynski B, Kirsch-
mann V, Baur X. Challenge from methacholine , natural
rubber latex , or 4,4-diphenylmethane-diisocyanate in
workers with suspected sensitisation affects exhaled ni-
tric oxide (change in exhaled NO levels after allergen
challenges). Int. Arch. Occup. Environ. Health 2000;73:
181-186.
7. Bates CA, Silkoff PE. Exhaled nitric oxide in asthma :
From bench to bedside. J. Allergy Clin. Immunol. 2003;
111:256-262.
8. Henriksen AH, Sue-Chu M, Holmen TL, Langhammer A,
Bjermer L. Exhaled and nasal NO levels in allergic rhini-
tis : relation to sensitisation, pollen season and bronchial
hyperresponsiveness. Eur. Respir. J. 1999;13:301-306.
9. Gratziou C, Rovina N, Lignos M, Vogiatzis I, Roussos C.
Exhaled nitric oxide in seasonal allergic rhinitis : influ-
Allergology International Vol 54, No1, 2005 www.js-allergol.gr.jp 157
NO in Isocyanate Workers
ence of pollen season and therapy. Clin. Exp. Allergy 2001;
31:409-416.
10. Latza U, Baur X, Malo JL. Isocyanate-induced health ef-
fects. In : JV Bakke , Norn JO , Thorud S (eds) . Inter-
national consensus report on : Isocyanates―Risk assess-
ment and management, Appendices 10.2.1. Gjovik:Norwe-
gian Labour Inspection Authority, 2002;37-51. Available
from: URL: http:www.arbeidstilsynet.nopublikasjoner
rapporterrapport1eng.html.
11. Bernstein DI, Korbee L, Stauder T et al. The low preva-
lence of occupational asthma and antibody-dependent
sensitization to diphenylmethane diisocyanate in a plant
engineered for minimal exposure to diisocyanates. J. Al-
lergy Clin. Immunol. 1993;92:387-396.
12. Malo JL, Ghezzo H, Elie R. Occupational asthma caused
by isocyanates. Am. J. Respir. Crit. Care Med. 1999;159:
1879-1883.
13. Baur X, Marek W, Ammon J et al. Respiratory and other
hazards of isocyanates. Int. Arch. Occup. Environ. Health
1994;66:141-152.
14. Redlich CA, Karol MH. Diisocyanate asthma : clinical as-
pects and immunopathogenesis. Int. Immunopharmacol.
2002;2:213-224.
15. Wisnewski AV, Redlich CA. Recent developments in di-
isocyanate asthma. Curr. Opin. Allergy Clin. Immunol.
2001;1:169-175.
16. Baur X, Chen Z, Flagge A, Posch A, Raulf-Heimsoth M.
EAST and CAP specificity for the evaluation of IgE and
IgG antibodies to diisocyanate-HSA conjugates. Int. Arch.
Allergy Immunol. 1996;110:332-338.
17. Baur X, Huber H, Degens P, Allmers H, Ammon J. Rela-
tion between occupational asthma case history, bronchial
methacholine challenge, and specific test in patients with
suspected occupational asthma. Am. J. Ind. Med. 1998;33:
114-122.
18. Recommendations for standardized procedures for the
online and offline measurement of exhaled lower respira-
tory nitric oxide and nasal nitric oxide in adults and chil-
dren― 1999. American Thoracic Society. Am. J. Respir.
Crit. Care Med. 1999;160:2104-2117.
19. Kharitonov SA, Robbins RA, Yates DH, Keatings V, Bar-
nes PJ. Acute and chronic effects of cigarette smoking on
exhaled nitric oxide. Am. J. Respir. Crit. Care Med. 1995;
152:609-612.
20. Robbins RA, Floreani AA, von Essen SG et al. Measure-
ment of exhaled nitric oxide by three different techniq-
ues. Am. J. Respir. Crit. Care Med. 1996;153:1631-1635.
21. Henriksen AH, Sue-Chu M, Holmen TL, Langhammer A,
Bjermer L. Exhaled and nasal NO levels in allergic rhini-
tis : relation to sensitisation, pollen season and bronchial
hyperresponsiveness. Eur. Respir. J. 1999;13:301-306.
22. Gratziou C, Rovina N, Lignos M, Vogiatzis I, Roussos C.
Exhaled nitric oxide in seasonal allergic rhinitis : influ-
ence of pollen season and therapy. Clin. Exp. Allergy 2001;
31:409-416.
23. Gratziou C, Lignos M, Dassiou M, Roussos C. Influence
of atopy on exhaled nitric oxide in patients with stable
asthma. Eur. Respir. J. 1999;14:897-901.
24. Obata H, Dittrick M, Chan H, Chan-Yeung M. Sputum
eosinophils and exhaled nitric oxide during late asthmatic
reactions in patients with western red cedar asthma. Eur.
Respir. J. 1999;13:489-495.
25. Dupont LJ, Rochette F, Demedts MG, Verleden GM. Ex-
haled nitric oxide correlates with airway hyperresponsive-
ness in steroid-naive patients with mild asthma. Am. J.
Respir. Crit. Care Med. 1998;157:894-898.
26. Henriksen AH, Lingaas-Holmen T, Sue-Chu M, Bjermer
L. Combined use of exhaled nitric oxide and airway hy-
perresponsiveness in characterizing asthma cases in a
large population survey. Eur. Respir. J. 2000;15:849-855.
27. Mapp CE, Saetta P, Maestrelli P et al. Mechanism and pa-
thology of occupational asthma. Eur. Respir. J. 1994;7:544-
554.
158 Allergology International Vol 54, No1, 2005 www.js-allergol.gr.jp
Baur X et al.
